|
Video: What is a Stock Split?
|
|
Mustang Bio is a clinical-stage biopharmaceutical company focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases. Co.'s pipeline is focused in three main areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. Co. is developing CAR T therapies for hematologic malignancies in partnership with City of Hope National Medical Center (COH) targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutch targeting CD20 (MB-106). Co. is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103) and PSCA (MB-105). According to our MBIO split history records, Mustang Bio has had 1 split. | |
|
Mustang Bio (MBIO) has 1 split in our MBIO split history database. The split for MBIO took place on April 04, 2023. This was a 1 for 15 reverse split, meaning for each 15 shares of MBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Mustang Bio conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MBIO split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Mustang Bio shares, starting with a $10,000 purchase of MBIO, presented on a split-history-adjusted basis factoring in the complete MBIO split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/23/2017 |
|
End date: |
10/04/2024 |
|
Start price/share: |
$174.15 |
|
End price/share: |
$0.22 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.87% |
|
Average Annual Total Return: |
-60.88% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$12.52 |
|
Years: |
7.12 |
|
|
|
Date |
Ratio |
04/04/2023 | 1 for 15 |
|
|